The pivotal role of pathology in the management of lung cancer

Journal of Thoracic Disease

Volumn 5, Issue SUPPL.5, 2013, Pages

  Davidson, Morgan R ^a,b   Gazdar, Adi F ^c,d   Clarke, Belinda E ^a,e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Lung neoplasms; Non small cell lung carcinoma (NSCLC); Pathology; small cell lung carcinoma (SCLC)

Indexed keywords

ADENOSQUAMOUS CARCINOMA; CANCER CLASSIFICATION; CANCER CYTODIAGNOSIS; CANCER GROWTH; CANCER SURVIVAL; CARCINOID; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOLECULAR DIAGNOSIS; REVIEW; SALIVARY GLAND CARCINOMA; SARCOMATOID CARCINOMA;

EID: 84898736387     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.08.43     Document Type: Review

References (126)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127, 2893-917.
2. Australian Bureau of Statistics. Causes of Death Australia 2009. Australian Government, ABS. 2011. http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lat estproducts/3303.0Contents2009?opendocument&tabname=Summary&pr odno=3303.0&issue=2009&num=&view=. Accessed 26 February 2012.
3. Naruke T, Tsuchiya R, Kondo H, et al. Implications of staging in lung cancer. Chest 1997, 112, 242S-8S.
4. Nesbitt JC, Putnam JB Jr, Walsh GL, et al. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 1995, 60, 466-72.
5. Australian Bureau of Statistics. Causes of Death, Australia, 2004. Australian Government, ABS. 2006. http://www.abs.gov.au/Ausstats/abs@.nsf/b066 60592430724fca2568b5007b8619/c67a858ba00cb846ca2568a9001393c 6!OpenDocument. Accessed 2 October 2006.
6. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004, 101, 3-27.
7. Australian Institute of Health and Welfare (AIHW) Cancer Australia (CA) and Australian Association of Cancer Registries (AACR). Cancer survival and prevalence in Australia: cancers diagnosed from 1982 to 2004. Canberra: AIHW2008. Report No.: Cancer Series. No. 42: Cat. No. 38.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100, 57-70.
9. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61, 759-67.
10. Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science 2002, 297, 63-4.
11. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12, 175-80.
12. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. WHO/ IASLC classification of lung and pleural tumours. Lyon: IARC Press, 2004.
13. Fong KM, Bowman RV, Fielding D, et al. Queensland integrated lung cancer outcomes project (qilcop): initial accrual and preliminary data from the first 30 months. Respirology 2003, 8 Suppl:A53.
14. Kumar V, Abbas A, Aster J. Robbins Basic Pathology. 9th ed. Philadelphia, PA: Elsevier/Saunders, 2013.
15. Auerbach O, Forman JB, Gere JB, et al. Changes in the bronchial epithelium in relation to smoking and cancer of the lung; a report of progress. N Engl J Med 1957, 256, 97-104.
16. Auerbach O, Stout AP, Hammond EC, et al. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med 1961, 265, 253-67.
17. Zochbauer-Muller S, Gazdar AF, Minna JD. Molecular pathogenesis of lung cancer. Annu Rev Physiol 2002, 64, 681-708.
18. Niklinski J, Niklinska W, Chyczewski L, et al. Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications. Eur J Cancer Prev 2001, 10, 213-26.
19. Wistuba, II, Gazdar AF. Characteristic genetic alterations in lung cancer. Methods Mol Med 2003, 74, 3-28.
20. Wistuba, II, Behrens C, Milchgrub S, et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999, 18, 643-50.
21. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6, 244-85.
22. Wistuba, II, Gazdar AF. Lung cancer preneoplasia. Annu Rev Pathol 2006, 1, 331-48.
23. Lantuejoul S, Salameire D, Salon C, et al. Pulmonary preneoplasia--sequential molecular carcinogenetic events. Histopathology 2009, 54, 43-54.
24. Sakurai H, Dobashi Y, Mizutani E, et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment. Ann Thorac Surg 2004, 78, 1728-33.
25. Vazquez M, Carter D, Brambilla E, et al. Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications. Lung Cancer 2009, 64, 148-54.
26. Yamato Y, Tsuchida M, Watanabe T, et al. Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung. Ann Thorac Surg 2001, 71, 971-4.
27. Yoshida J, Nagai K, Yokose T, et al. Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience. J Thorac Cardiovasc Surg 2005, 129, 991-6.
28. Koike T, Togashi K, Shirato T, et al. Limited resection for noninvasive bronchioloalveolar carcinoma diagnosed by intraoperative pathologic examination. Ann Thorac Surg 2009, 88, 1106-11.
29. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995, 75, 2844-52.
30. Tomashefski JF Jr, Connors AF Jr, Rosenthal ES, et al. Peripheral vs central squamous cell carcinoma of the lung. A comparison of clinical features, histopathology, and survival. Arch Pathol Lab Med 1990, 114, 468-74.
31. Davies SJ, Gosney JR, Hansell DM, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax 2007, 62, 248-52.
32. Wistuba, II, Berry J, Behrens C, et al. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res 2000, 6, 2604-10.
33. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008, 359, 1367-80.
34. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362, 2380-8.
35. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361, 947-57.
36. Marks JL, Broderick S, Zhou Q, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008, 3, 111-6.
37. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97, 339-46.
38. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006, 118, 257-62.
39. Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006, 24, 1700-4.
40. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers--a different disease. Nat Rev Cancer 2007, 7, 778-90.
41. Palmer RH, Vernersson E, Grabbe C, et al. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009, 420, 345-61.
42. Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 2009, 27, 4232-5.
43. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010, 16, 5581-90.
44. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011, 6, 459-65.
45. Moreira AL, Thornton RH. Personalized medicine for non-small-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing. Clinical lung cancer 2012, 13, 334-9.
46. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013, 8, 823-59.
47. Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010, 29, 49-60.
48. Roberts PJ, Stinchcombe TE, Der CJ, et al. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010, 28, 4769-77.
49. Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 2011, 223, 219-29.
50. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005, 65, 1642-6.
51. Buttitta F, Barassi F, Fresu G, et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 2006, 119, 2586-91.
52. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010, 2, 62ra93.
53. Monica V, Scagliotti GV, Ceppi P, et al. Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. Clin Cancer Res 2009, 15, 7547-52.
54. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107, 1589-96.
55. Nicolson MC, Fennell DA, Ferry D, et al. Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non-Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial. J Thorac Oncol 2013, 8, 930-9.
56. Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapynaive patients with extensive-stage small-cell lung cancer. J Clin Oncol 2009, 27, 4787-92.
57. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in nonsmall-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355, 983-91.
58. Custodio AB, Gonzalez-Larriba JL, Bobokova J, et al. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J Thorac Oncol 2009, 4, 891-910.
59. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22, 2184-91.
60. Maeshima AM, Maeshima A, Asamura H, et al. Histologic prognostic factors for small-sized squamous cell carcinomas of the peripheral lung. Lung Cancer 2006, 52, 53-8.
61. Travis WD. Pathology of lung cancer. Clin Chest Med 2011, 32, 669-92.
62. Cagle PT, Allen TC, Dacic S, et al. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med 2011, 135, 110-6.
63. Charloux A, Quoix E, Wolkove N, et al. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 1997, 26, 14-23.
64. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011, 24, 653-64.
65. Miyoshi T, Satoh Y, Okumura S, et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 2003, 27, 101-9.
66. Tsutsumida H, Nomoto M, Goto M, et al. A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Mod Pathol 2007, 20, 638-47.
67. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010, 34, 1155-62.
68. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013, 8, 52-61.
69. Yanagawa N, Shiono S, Abiko M, et al. New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J Thorac Oncol 2013, 8, 612-8.
70. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011, 6, 1496-504.
71. Howlader N NA, Krapcho M, Garshell J, et al. eds. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
72. Sun Z, Aubry MC, Deschamps C, et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg 2006, 131, 1014-20.
73. Sawabata N, Asamura H, Goya T, et al. Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002. J Thorac Oncol 2010, 5, 1369-75.
74. Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008, 113, 5-21.
75. Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 2010, 134, 1628-38.
76. Australia AIoHaWC. Lung cancer in Australia: an overview. Canberra: AIHW2011. Report No.: Cancer series no. 64. Cat. no. CAN 58..
77. Fan Z, Schraeder R. The changing pathology of lung cancer. Surg Oncol Clin N Am 2011, 20, 637-53.
78. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society Classification. Arch Pathol Lab Med 2013, 137, 668-84.
79. Lack EE, Harris GB, Eraklis AJ, et al. Primary bronchial tumors in childhood. A clinicopathologic study of six cases. Cancer 1983, 51, 492-7.
80. Fitzgibbons PL, Kern WH. Adenosquamous carcinoma of the lung: a clinical and pathologic study of seven cases. Hum Pathol 1985, 16, 463-6.
81. Naunheim KS, Taylor JR, Skosey C, et al. Adenosquamous lung carcinoma: clinical characteristics, treatment, and prognosis. Ann Thorac Surg 1987, 44, 462-6.
82. Ben Y, Yu H, Wang Z, et al. Adenosquamous lung carcinoma: clinical characteristics, surgical treament and prognosis. Chin Med Sci J 2000, 15, 238-40.
83. Dacic S, Finkelstein SD, Sasatomi E, et al. Molecular pathogenesis of pulmonary carcinosarcoma as determined by microdissection-based allelotyping. Am J Surg Pathol 2002, 26, 510-6.
84. Nappi O, Glasner SD, Swanson PE, et al. Biphasic and monophasic sarcomatoid carcinomas of the lung. A reappraisal of 'carcinosarcomas' and 'spindle-cell carcinomas'. Am J Clin Pathol 1994, 102, 331-40.
85. Thompson L, Chang B, Barsky SH. Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. Am J Surg Pathol 1996, 20, 277-85.
86. Nakajima M, Kasai T, Hashimoto H, et al. Sarcomatoid carcinoma of the lung: a clinicopathologic study of 37 cases. Cancer 1999, 86, 608-16.
87. Ro JY, Chen JL, Lee JS, et al. Sarcomatoid carcinoma of the lung. Immunohistochemical and ultrastructural studies of 14 cases. Cancer 1992, 69, 376-86.
88. Travis WD. Sarcomatoid neoplasms of the lung and pleura. Arch Pathol Lab Med 2010, 134, 1645-58.
89. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975, 70, 606-12.
90. Huang J, Behrens C, Wistuba I, et al. Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis. Ann Diagn Pathol 2001, 5, 321-9.
91. Hiroshima K, Toyozaki T, Kohno H, et al. Synchronous and metachronous lung carcinomas: molecular evidence for multicentricity. Pathol Int 1998, 48, 869-76.
92. Girard N, Deshpande C, Lau C, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 2009, 33, 1752-64.
93. Neugut AI, Sherr D, Robinson E, et al. Differences in histology between first and second primary lung cancer. Cancer Epidemiol Biomarkers Prev 1992, 1, 109-12.
94. Inamura K, Satoh Y, Okumura S, et al. Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol 2005, 29, 660-5.
95. Leong PP, Rezai B, Koch WM, et al. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1998, 90, 972-7.
96. Geurts TW, Nederlof PM, van den Brekel MW, et al. Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? Clin Cancer Res 2005, 11, 6608-14.
97. Day TA, Davis BK, Gillespie MB, et al. Oral cancer treatment. Curr Treat Options Oncol 2003, 4, 27-41.
98. Keith RL, Miller YE. Lung cancer: genetics of risk and advances in chemoprevention. Curr Opin Pulm Med 2005, 11, 265-71.
99. Pereira TC, Share SM, Magalhaes AV, et al. Can we tell the site of origin of metastatic squamous cell carcinoma? An immunohistochemical tissue microarray study of 194 cases. Appl Immunohistochem Mol Morphol 2011, 19, 10-4.
100. Doxtader EE, Katzenstein AL. The relationship between p16 expression and high-risk human papillomavirus infection in squamous cell carcinomas from sites other than uterine cervix: a study of 137 cases. Hum Pathol 2012, 43, 327-32.
101. Fong KM, Kida Y, Zimmerman PV, et al. Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer. Cancer Res 1995, 55, 4268-72.
102. Klein F, Amin Kotb WF, Petersen I. Incidence of human papilloma virus in lung cancer. Lung Cancer 2009, 65, 13-8.
103. Suo Z, Holm R, Nesland JM. Squamous cel l carcinomas. An immunohistochemical study of cytokeratins and involucrin in primary and metastatic tumours. Histopathology 1993, 23, 45-54.
104. Kaufmann O, Fietze E, Mengs J, et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001, 116, 823-30.
105. Sigel CS, Moreira AL, Travis WD, et al. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol 2011, 6, 1849-56.
106. Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011, 24, 1348-59.
107. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer 2011, 117, 3416-23.
108. Mukhopadhyay S. Utility of small biopsies for diagnosis of lung nodules: doing more with less. Mod Pathol 2012, 25 Suppl 1:S43-57.
109. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010, 41, 20-5.
110. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010, 5, 436-41.
111. Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010, 5, 442-7.
112. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011, 35, 15-25.
113. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000, 13, 962-72.
114. Pelosi G, Rossi G, Cavazza A, et al. ΔNp63 (p40) Distribution Inside Lung Cancer: A Driver Biomarker Approach to Tumor Characterization. Int J Surg Pathol 2013, 21, 229-39.
115. Candi E, Dinsdale D, Rufini A, et al. TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle 2007, 6, 274-85.
116. Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012, 25, 405-15.
117. Pelosi G, Fabbri A, Bianchi F, et al. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing nonsmall cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol 2012, 7, 281-90.
118. Yang X, Lu H, Yan B, et al. ΔNp63 versatilely regulates a Broad NF-kappaB gene program and promotes squamous epithelial proliferation, migration, and inflammation. Cancer Res 2011, 71, 3688-700.
119. Saintigny P, El-Naggar AK, Papadimitrakopoulou V, et al. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res 2009, 15, 6284-91.
120. Alsharif M, Carlo-Demovich J, Massey C, et al. Telecytopathology for immediate evaluation of fine-needle aspiration specimens. Cancer Cytopathol 2010, 118, 119-26.
121. Bulman W, Saqi A, Powell CA. Acquisition and processing of endobronchial ultrasound-guided transbronchial needle aspiration specimens in the era of targeted lung cancer chemotherapy. Am J Respir Crit Care Med 2012, 185, 606-11.
122. Wallace WA, Rassl DM. Accuracy of cell typing in nonsmall cell lung cancer by EBUS/EUS-FNA cytological samples. Eur Respir J 2011, 38, 911-7.
123. Layfield LJ, Bentz JS, Gopez EV. Immediate on-site interpretation of fine-needle aspiration smears: a cost and compensation analysis. Cancer 2001, 93, 319-22.
124. Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 2011, 32, 22-31.
125. Thunnissen E, Kerr KM, Herth FJ, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung cancer 2012, 76, 1-18.
126. Ellison G, Zhu G, Moulis A, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 2013, 66, 79-89.